Bax­ter CD­MO Bio­Phar­ma So­lu­tions names Fran­co Ne­gron as CEO ahead of pro­posed sale

Bax­ter’s CD­MO arm, Bio­Phar­ma So­lu­tions, has an­nounced a new CEO will take the reins fol­low­ing its pro­posed sale to pri­vate eq­ui­ty com­pa­ny Ad­vent In­ter­na­tion­al and in­vest­ment out­fit War­burg Pin­cus for $4 bil­lion.

Ad­vent and War­bug picked No­var­tis vet­er­an Fran­co Ne­gron to lead the charge. Ne­gron has more than 30 years of ex­pe­ri­ence in the man­u­fac­tur­ing and phar­ma in­dus­try, and pre­vi­ous­ly served as CEO of the med­ical tech­nol­o­gy com­pa­ny Api­Ject and held lead­er­ship po­si­tions at con­tract man­u­fac­tur­er Patheon be­fore Ther­mo Fish­er ac­quired it in 2017. He al­so served at Valeant Phar­ma­ceu­ti­cals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER